PMID- 26799405
OWN - NLM
STAT- MEDLINE
DCOM- 20160801
LR  - 20220311
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 1
DP  - 2016
TI  - The Features of Inflammation Factors Concentrations in Aqueous Humor of 
      Polypoidal Choroidal Vasculopathy.
PG  - e0147346
LID - 10.1371/journal.pone.0147346 [doi]
LID - e0147346
AB  - PURPOSE: To investigate the cytokine concentrations in the aqueous humor of 
      patients with refractory polypoidal choroidal vasculopathy (PCV). METHODS: Three 
      separate groups of patients were studied-refractory PCV (Group A, 41 eyes), 
      stable PCV (Group B, 39 eyes) and senile cataract (Group C, 44 eyes). Aqueous 
      humor samples were collected at two time points for Groups A and B-before the 
      first intravitreal ranibizumab injection and before the last injection. Aqueous 
      humor samples were collected prior to phacoemulsification in Group C. The 
      cytokine concentrations of interleukin 2, 6, and 8 (IL-2, IL-6, and IL-8), tumor 
      necrosis factor alpha (TNF-alpha), monocyte chemotactic protein 1 (MCP-1), and vascular 
      endothelial growth factor (VEGF) were measured by cytometric bead array and flow 
      cytometry. RESULTS: Before the first treatment, the MCP-1, VEGF, and TNF-alpha levels 
      in Group A were significantly higher than those in Group C (P < 0.05), and the 
      MCP-1 and VEGF levels in Group A were significantly higher than those in Group B 
      (P < 0.05). Significantly higher MCP-1 and VEGF levels were seen in Group B 
      compared to Group C (P < 0.05). Before the final treatment, the MCP-1, VEGF, and 
      TNF-alpha concentrations in Group A were significantly higher than those in Group B 
      (P < 0.05) and Group C (P < 0.05). IL-2 levels were significantly lower in Group 
      A compared to Group B (P < 0.05) and Group C (P < 0.05). CONCLUSION: Inflammatory 
      cytokines such as MCP-1, VEGF, and TNF-alpha may be associated with the pathogenesis 
      of both stable and refractory PCV.
FAU - Hu, Jie
AU  - Hu J
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Leng, Xuan
AU  - Leng X
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Hu, Yijun
AU  - Hu Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Atik, Alp
AU  - Atik A
AD  - Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
FAU - Song, Xin
AU  - Song X
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Li, Zhixi
AU  - Li Z
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Liu, Yuhua
AU  - Liu Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Lu, Lin
AU  - Lu L
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160122
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Aqueous Humor/*metabolism
MH  - Chemokine CCL2/*metabolism
MH  - China
MH  - Choroid/*blood supply/immunology/pathology
MH  - Choroiditis/*pathology
MH  - Female
MH  - Humans
MH  - Inflammation/pathology
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab/therapeutic use
MH  - Retinal Pigment Epithelium/blood supply/pathology
MH  - Retrospective Studies
MH  - Tumor Necrosis Factor-alpha/*metabolism
MH  - Vascular Endothelial Growth Factor A/*metabolism
PMC - PMC4723149
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2016/01/23 06:00
MHDA- 2016/08/02 06:00
PMCR- 2016/01/22
CRDT- 2016/01/23 06:00
PHST- 2015/08/04 00:00 [received]
PHST- 2015/12/31 00:00 [accepted]
PHST- 2016/01/23 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2016/08/02 06:00 [medline]
PHST- 2016/01/22 00:00 [pmc-release]
AID - PONE-D-15-32363 [pii]
AID - 10.1371/journal.pone.0147346 [doi]
PST - epublish
SO  - PLoS One. 2016 Jan 22;11(1):e0147346. doi: 10.1371/journal.pone.0147346. 
      eCollection 2016.